IP Library › Granted Patent US 9,919,036
Granted Patent B2
US 9,919,036 · App. 14/606,729 · Granted Mar 20, 2018

Identification of tumor-associated antigens for diagnosis and therapy

Inventors: Ugur Sahin (Mainz, DE); Ozlem Tureci (Mainz, DE); Michael Koslowski (Mainz, DE); Dirk Usener (Wiesbaden, DE)
Assignees: GANYMED PHARMACEUTICALS AG; JOHANNES GUTENBERG-UNIVERSITAT MAINZ
A61K39/0011A61K45/06C07K14/4748C07K16/2803C07K16/30C12Q1/6886G01N33/574A61K2039/5256A61K2039/54A61K2039/57A61K2039/572C07K2317/34C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,919,036
App. No.
14/606,729
Granted
Mar 20, 2018
Kind
B2
Abstract

The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Claims (31)

1. An isolated antibody that binds specifically to a protein or polypeptide or to a part thereof, the protein or polypeptide being encoded by a nucleic acid that is:

(a) the nucleic acid of SEQ ID NO. 1, or

(b) a nucleic acid that has at least 95% sequence identity with the nucleic acid of (a), wherein

the antibody is a monoclonal antibody, or is an antigen binding fragment of the monoclonal antibody; and

wherein the antibody binds to an epitope comprised in a sequence selected from the group consisting of SEQ. ID. NOs. 59 and 69.

2. The isolated antibody as claimed in claim 1 , wherein the protein or polypeptide comprises the amino acid sequence of SEQ ID NO. 2.

3. A conjugate comprising the isolated antibody as claimed in claim 1 , further comprising a therapeutic or diagnostic agent.

4. The conjugate as claimed in claim 3 , wherein the therapeutic or diagnostic agent is a toxin.

5. A conjugate comprising the isolated antibody as claimed in claim 2 , further comprising a therapeutic or diagnostic agent.

6. The conjugate as claimed in claim 5 , wherein the therapeutic or diagnostic agent is a toxin.

7. The isolated antibody of claim 1 , wherein the antibody binds to an epitope comprised in SEQ. ID. NO. 59.

8. The isolated antibody of claim 1 , wherein the antibody binds to an epitope comprised in SEQ. ID. NO. 69.

9. A pharmaceutical composition, comprising a monoclonal antibody selective for cells expressing or abnormally expressing a tumor-associated antigen, the tumor-associated antigen having a sequence encoded by a nucleic acid that is:

(a) a nucleic acid which comprises the nucleic acid sequence of SEQ ID NO. 1, or

(b) a nucleic acid that has at least 95% sequence identity with the nucleic acid of (a), and

wherein the antibody binds to an epitope comprised in a sequence selected from the group consisting of SEQ. ID. NOs. 59 and 69.

10. The pharmaceutical composition as claimed in claim 9 , wherein the antibody binds selectively to the tumor-associated antigen.

11. The pharmaceutical composition as claimed in claim 9 wherein the antibody is coupled to a therapeutic agent or a diagnostic agent.

12. The conjugate as claimed in claim 11 , wherein the therapeutic or diagnostic agent is a toxin.

13. The pharmaceutical composition as claimed in claim 9 , wherein the tumor-associated antigen comprises the amino acid sequence of SEQ ID NO. 2.

14. The pharmaceutical composition of claim 9 , wherein the antibody binds to an epitope comprised in SEQ. ID. NO. 59.

15. The pharmaceutical composition of claim 9 , wherein the antibody binds to an epitope comprised in SEQ. ID. NO. 69.

16. A pharmaceutical composition, comprising a monoclonal antibody which binds to a tumor-associated antigen or a part thereof, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:

(a) a nucleic acid which comprises the nucleic acid sequence of SEQ ID NO. 1, and

(b) a nucleic acid that has at least 95% sequence identity with the nucleic acid of (a), and

wherein the antibody binds to an epitope comprised in a sequence selected from the group consisting of SEQ. ID. NOs. 59 and 69.

17. The pharmaceutical composition as claimed in claim 16 wherein the antibody is coupled to a therapeutic agent or a diagnostic agent.

18. The conjugate as claimed in claim 17 , wherein the therapeutic or diagnostic agent is a toxin.

19. The pharmaceutical composition as claimed in claim 16 , wherein the tumor-associated antigen comprises the amino acid sequence of SEQ ID NO. 2.

20. The pharmaceutical composition of claim 16 , wherein the antibody binds to an epitope comprised in SEQ. ID. NO. 59.

21. The pharmaceutical composition of claim 16 , wherein the antibody binds to an epitope comprised in SEQ. ID. NO. 69.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INADVERTENT INCLUSION OF PAT. NOS. 9044382 AND 9775785 PREVIOUSLY RECORDED ON REEL 052032 FRAME 0271. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 22, 2020
From: JOHANNES GUTENBERG-UNIVERSITAT MAINZ
To: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Reel/Frame 052997/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2020
From: JOHANNES GUTENBERG-UNIVERSITAT MAINZ
To: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Reel/Frame 052032/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2020
From: GANYMED PHARMACEUTICALS GMBH
To: ASTELLAS PHARMA INC
Reel/Frame 052032/0041 →
CHANGE OF NAME Recorded Mar 5, 2020
From: GANYMED PHARMACEUTICALS AG
To: GANYMED PHARMACEUTICALS GMBH
Reel/Frame 052114/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2015
From: SAHIN, UGUR; TURECI, OZLEM; KOSLOWSKI, MICHAEL; USENER, DIRK
To: GANYMED PHARMACEUTICALS AG; JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Reel/Frame 035284/0156 →
Priority Claims (1)
EP 05019786 · Sep 12, 2005 · regional
Continuity (3)
Division 13086176 · Apr 13, 2011
Continuation 12066399
Related Publication 20150197576A1 · Jul 16, 2015